KRYS Dec 2024 210.000 call
| Previous close | 33.21 |
| Open | N/A |
| Bid | 23.50 |
| Ask | 28.00 |
| Strike | 210.00 |
| Expiry date | 2024-12-20 |
| Day's range | 33.21 - 33.21 |
| Contract range | N/A |
| Volume | |
| Open interest | 2 |
PR NewswireKKR, CrowdStrike Holdings and GoDaddy Set to Join S&P 500; Others to Join S&P MidCap 400 and S&P SmallCap 600
S&P Dow Jones Indices ("S&P DJI") will make the following changes to the S&P 500, S&P MidCap 400, and S&P SmallCap 600 indices effective prior to the open of trading on Monday, June 24, to coincide with the quarterly rebalance. The changes ensure each index is more representative of its market capitalization range. All companies being added to the S&P 500 are more representative of the large-cap market space, all companies being added to the S&P MidCap 400 are more representative of the mid-cap
GlobeNewswireKrystal Biotech to Present at Goldman Sachs 45th Annual Global Healthcare Conference
PITTSBURGH, June 05, 2024 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that the Company will participate in the Goldman Sachs 45th Annual Global Healthcare Conference on June 11, 2024, in Miami. Krish S. Krishnan, Chairman and Chief Executive Officer, will take part in a fireside chat scheduled at 10:40 am ET and host investor meetings throughout the day. A webcast of the presentation will be available here be
Insider MonkeyIs Krystal Biotech, Inc. (NASDAQ:KRYS) the Premier Gene Therapy Stock for Your Portfolio?
We recently compiled a list of the 9 Best Gene Therapy Stocks to Buy Now and in this article, we discuss whether Krystal Biotech, Inc. (NASDAQ:KRYS) is the premier gene therapy stock for your portfolio. Gene therapy involves treating illnesses by modifying, replacing, or supplementing faulty or missing genes responsible for a disease. This approach […]
